In turn, this suggests that Nivolumab might improve the function of ILC2s and CD117+ ILCs not by directly affecting the interaction between melanoma cells and ILCs but rather by disrupting additional interactions mediated by PD-1 in vivo. This evidence concerns the gene KIT and melanoma.